Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Leases (2016 - 2025)

ImmunityBio (IBRX) has disclosed Current Leases for 10 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 0.92% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, up 0.92% year-over-year, with the annual reading at $7.5 million for FY2025, 0.92% up from the prior year.
  • Current Leases for Q4 2025 was $7.5 million at ImmunityBio, up from $7.3 million in the prior quarter.
  • The five-year high for Current Leases was $7.5 million in Q4 2025, with the low at $1.4 million in Q3 2022.
  • Average Current Leases over 5 years is $4.9 million, with a median of $5.2 million recorded in 2021.
  • The sharpest move saw Current Leases crashed 55.57% in 2022, then skyrocketed 326.21% in 2023.
  • Over 5 years, Current Leases stood at $3.0 million in 2021, then decreased by 11.99% to $2.6 million in 2022, then soared by 97.89% to $5.2 million in 2023, then surged by 42.37% to $7.5 million in 2024, then grew by 0.92% to $7.5 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $7.5 million, $7.3 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.